newsfilter
← Latest News
GlobeNewswire·

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs